Association of Plasma N-terminal Pro-Brain Natriuretic Peptide Levels With the Burden of Coronary Artery Disease
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: BNP.
- Who it may be relevant to
- Registry conditions: Chronic Coronary Syndrome, Chronic Coronary Total Occlusion, Coronary Arterial Disease (CAD), Stable Chronic Angina. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Italy
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Association of Plasma N-terminal Pro-Brain Natriuretic Peptide Levels With the Burden of Coronary Artery Disease: Insights From a Real-World Cohort
Overview
This study aim to investigate the association between plasma NT-proBNP levels and the presence, extent and severity of stenosis in patients with suspected coronary artery disease.
Detailed description
The investigators prospectively measured plasma NT-proBNP levels in consecutive patients referred to the center for elective diagnostic coronary angiography due to symptoms or signs of coronary artery disease over a two- year period. Patients with conditions known to elevate NT-proBNP levels, including heart failure, severe valvular disease, atrial fibrillation, severe chronic kidney disease (eGFR \< 30 mL/min), prior coronary artery bypass grafting, or age over 80 years, were excluded.
Interventions
- Diagnostic test BNP
Measurement of plasma NT-proBNP level.
Primary outcome measures
- Association between plasma NT-proBNP levels and the presence, extension and severity of angiographic lesions in patients with suspected CAD. [Time frame: Plasma NT-proBNP levels are quantified on the morning before coronary angiography. The CAD burden is independently evaluated by two experienced interventional cardiologists periprocedurally and immediately after the coronary angiography.]
Eligibility criteria
Inclusion criteria
- patient referred for elective coronary angiography due to suspected CAD.
- NT-proBNP measurement during hospitalization
Exclusion criteria
- heart failure
- severe valvular disease
- atrial fibrillation
- severe chronic kidney disease (eGFR < 30 mL/min)
- prior coronary artery bypass grafting
- age over 80 years
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Italy · 2 centers
- IRCCS San Raffaele Hospital — Milan
- IRCCS San Raffaele Hospital — Milan
Identifiers
NCT: NCT07013344 · BNP-CAD-HSR-2025